Thus, overexpression and activation of PPARγ might have high potential for treating SCD-associated pulmonary hypertension through HUWE1-mediated downregulation of NF-κb signaling (Jang et al., 2021). The gene discussed is PPARG; the disease is Schnyder corneal dystrophy.